Skip to content
Screener

Lantheus Holdings LNTH Accrued Research And Development Costs Current

Accrued Research And Development Costs Current at other companies

Alumis Inc. logo
Alumis Inc.ALMS
$35.96M+3.6%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$1.82M-29.1%
Assembly Biosciences logo
Assembly BiosciencesASMB
$1.54M-27.0%
Roivant Sciences logo
Roivant SciencesROIV
$113.44M+128%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$98M+60.7%
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
$2.77M+210%

Other financials

Income statement

See full
Revenue$388.2M+2.7%
Gross profit$241.9M+0.4%
Operating income$100.2M+13.9%
Net income$75.0M-4.7%
EPS (diluted)$1.11-0.9%

Balance sheet

See full
Cash & equivalents$595.0M-14.7%
Total debt$626.8M+1.5%
Total equity$1.3B+12.4%
Total assets$2.4B+14.1%

Cash flow

See full
Operating cash flow$92.2M+5.9%
CapEx$2.3M-70.7%
Free cash flow$89.9M+13.5%

Valuation

See full
Market cap$6.59B+72.8%
Enterprise value$6.62B+77.4%
P/E23.9×+10.5×
P/S4.2×+1.7×

Profitability

See full
Gross margin60.1%-3.6pp
Operating margin19.4%-9.4pp
Net margin17.7%-0.9pp
FCF margin24.9%-6.6pp

Returns & leverage

See full
Return on equity22.2%-3.6pp
Debt / equity0.5×-0.1×
Current ratio3.1×-1.2×

Where this comes from

Reported directly by Lantheus Holdings in its filing.

Tagged under the XBRL concept lnth:AccruedResearchAndDevelopmentCostsCurrent.

The source filing: Lantheus Holdings’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 8:01 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336795
(in thousands)June 30, 2026December 31, 2025
Freight, distribution and operations73,39775,995
Accrued rebates and discounts70,46466,448
Accrued professional fees16,56626,511
Accrued research and development expenses12,00312,964
Accrued sales and marketing expenses36,0354,885
Income taxes payable4,0293,574
Short-term contingent consideration13,9193,882
Other14,6999,804

Item 1. Financial Statements

FAQ

What is Lantheus Holdings's accrued research and development costs current?
Lantheus Holdings (LNTH) reported accrued research and development costs current of $12M in Q2 2026.
How has Lantheus Holdings's accrued research and development costs current changed year-over-year?
Lantheus Holdings's accrued research and development costs current increased by 31.3% year-over-year, from $9.14M to $12M.
What is the long-term trend for Lantheus Holdings's accrued research and development costs current?
Over 2 years (2023 to 2025), Lantheus Holdings's accrued research and development costs current has grown at a 99.5% compound annual growth rate (CAGR), from $3.26M to $12.96M.
What does accrued research and development costs current mean?
This represents the accrued expenses for ongoing research and development activities that have been performed but not yet billed. It provides a window into the intensity and timing of the company's innovation pipeline and clinical trial progress. Significant changes in this metric can signal shifts in the pace of product development or R&D investment.

Ask your AI about Lantheus Holdings's accrued research and development costs current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude